Login to Your Account

Clinic roundup

Thursday, May 15, 2014
Amgen, of Thousand Oaks, Calif., said data from the phase III LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) study were published in the Journal of the American Medical Association.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription